(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 212.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Precigen's revenue in 2024 is $5,439,000.On average, 2 Wall Street analysts forecast PGEN's revenue for 2024 to be $1,241,904,875, with the lowest PGEN revenue forecast at $1,070,259,486, and the highest PGEN revenue forecast at $1,413,550,264. On average, 3 Wall Street analysts forecast PGEN's revenue for 2025 to be $9,949,374,501, with the lowest PGEN revenue forecast at $1,098,025,652, and the highest PGEN revenue forecast at $26,478,825,481.
In 2026, PGEN is forecast to generate $54,446,927,133 in revenue, with the lowest revenue forecast at $54,446,927,133 and the highest revenue forecast at $54,446,927,133.